University of Washington

Health Systems and Population Health

SCHOOL OF PUBLIC HEALTH

The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.


  1. Home


  2. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.


  3. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.

rakerr2

Roth JA, Carlson JJ, Xia F, Williamson T, Sullivan SD. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. J Manag Care Spec Pharm. 2020 Aug;26(8):981-

Upcoming Events

Full Calendar

News Categories